Demethylation of the HGK promoter in the 5-AZAC-treated T cells could not be demonstrated by pyrosquencing on the same clinical samples because only small number of peripheral blood T cells are available from drug-naïve T2D patients; therefore, other potential or indirect effects of 5-AZAC on these treated cells cannot be formally ruled out. Here, MAP4K4 is linked to type 2 diabetes mellitus.